Century Therapeutics’ (IPSC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a report released on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

Other research analysts also recently issued research reports about the company. Chardan Capital reduced their price objective on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Piper Sandler cut their price target on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC opened at $0.90 on Wednesday. The business has a fifty day moving average of $1.17 and a 200-day moving average of $1.55. Century Therapeutics has a twelve month low of $0.86 and a twelve month high of $5.51. The firm has a market cap of $76.53 million, a PE ratio of -0.49 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.47 million. During the same quarter last year, the company posted ($0.55) EPS. On average, analysts anticipate that Century Therapeutics will post -1.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after buying an additional 9,500 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics during the third quarter worth about $27,000. Rhumbline Advisers lifted its holdings in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after purchasing an additional 18,828 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Century Therapeutics by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after buying an additional 44,155 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.